



Cannasouth Highlights

- Vertically integrated biopharmaceutical company. Activities include advanced research, cultivation, product development, manufacture, and sales (seed to sale).
- Cannasouth was New Zealand’s first medicinal cannabis company to list on the New Zealand Stock Exchange (NZX:CBD) in June 2019.
- Developed next-generation Controlled Environment Agriculture (CEA) sealed greenhouses. The facility allows year-round cultivation of premium GACP/GMP compliant cannabis flower at industry-leading production costs and with a lower environmental impact than indoor operations.
- Pure New Zealand provenance, grown in the Waikato region, the agricultural heartland of New Zealand.
- Our people are our greatest assets. We have assembled a world-class team with over 220 years of combined GMP and pharmaceutical R&D experience.
- With significant Government funding via Callaghan Innovation, we are researching medicinal cannabis and drug delivery technology, optimising product performance, bioavailability, and patient outcomes.
- We will have a premium product range, encompassing dried flower to high quality oils.

Key Milestones

2019		2020		2021 (Planned)	
First medicinal cannabis company to list on NZX Main Board in June 2019	Purchased a 60% stake in Midwest Pharmaceuticals NZ Ltd to provide a GMP manufacturing facility for the Group, and core revenues while the medicinal cannabis market develops	Recruited additional top talent to join our team, covering Regulatory, Research, Quality, Operations, Finance and Sales	A heavily over-subscribed successful Share Purchase Plan (SPP) and wholesale placement capital-raise despite the Covid-19 lockdown in May 2020; raising \$6 million	As a good corporate citizen, refunded \$85,726 to the NZ government for COVID-19 financial assistance, after well-supported capital raising	Granted first commercial cultivation activity and possession to manufacture activity licences in September 2020
Established a joint venture, Cannasouth Cultivation Ltd, to grow and process cannabis	Commenced construction of a new energy-efficient, scalable, Controlled Environment Agriculture (CEA) commercial cannabis cultivation and processing facility	Secured funding for research projects from Callaghan Innovation	Successfully concluded a supply agreement with MediPharm Labs, Australia, in May 2020 to import Cannasouth own branded medicines	Cannasouth Cultivation Ltd appointed noted Colorado cultivator, Vera Cultivation, to supply the design and support the implementation of a state-of-the-art growing facility and growing systems	Submitted product assessment applications to the Medicinal Cannabis Agency in November 2020 for three imported Cannasouth own branded medicines
					Received additional cultivation licence for Cannasouth Cultivation facility
					Commissioning underway of a state-of-the-art cultivation facility
					Gain accreditation for Good Agricultural and Collection Practices (GACP) for flower production
					Development begins to add additional production capacities and capabilities at Midwest to extract and manufacture cannabis-based ingredients and finished medicines
					Expected first domestic sales of registered imported Cannasouth own branded products to New Zealand patients (subject to successful Medicinal Cannabis Agency assessment)

Cannasouth Licences

The New Zealand Medicinal Cannabis Scheme was launched on 1 April 2020. Cannasouth has applied for and received the following commercial licences and product registrations from the NZ Ministry of Health under the Scheme.

Entity	Licence	Status	Licencer
CBL	Medicinal Cannabis Licence (Cultivation, Possess for Manufacture, and Supply Activities)	✔ Approved	Ministry of Health
CBL	Licence to deal in controlled drugs	✔ Approved	Ministry of Health
CBL	Own brand imported medicinal cannabis product registration applications (x3)	✔ Submitted	Ministry of Health
CCL	Medicinal Cannabis Licence (Cultivation Activity)	✔ Approved	Ministry of Health
CCL	Medicinal Cannabis Licence (Supply Activity)	✔ Planned	Ministry of Health
MW	Medicinal Cannabis Licence (Possess for Manufacture and Supply Activities)	✔ Planned	Ministry of Health
MW	GMP Manufacturing Medicines Licence	✔ Planned	Ministry of Health
MW	GMP Wholesale Licence	✔ Approved	Ministry of Health
MW	GMP Licence to pack Medicines	✔ Approved	Ministry of Health
MW	CTFA (Cosmetic) GMP Licence	✔ Approved	Cosmetics New Zealand
MW	Biogro Organic Certification	✔ Approved	BioGro New Zealand
MW	NP3 (Food Act 2014) Licence to Manufacture Food Products	✔ Approved	Hastings District Council



Research & Development


Our R&D Team includes highly qualified and experienced scientists and laboratories equipped with some of the most advanced technology for targeting and isolating cannabinoids to feed into our formulation and clinical development programmes. Cannasouth has been successful in achieving Government funding via Callaghan Innovation for many of our research initiatives including:

Grant Type	Research	Status
Fellowship Grant	PhD: the Extraction of bioactives using Supercritical Fluid CO2 extraction, short path molecular distillation and purification research	In final year of three-year programme
	MSc: Tissue Culture to identify and optimise cultivation processes	Submitted February 2021
	MSc: To create a cannabinoid and receptor docking library using computational chemistry	Commenced March 2021
Project Grant	PhD: Drug Discovery, Neuropathic pain research In-house Research: Improved Drug Delivery technologies	Half-way into a three-year programme
Career Grant	Placement of a Fellowship Grant MSc student into full-time R&D role	February to August 2021

This research combined with our pre-clinical studies allows Cannasouth to search for genuine unique IP opportunities, develop clinical trial strategies, and develop innovative new products and formulations for both the local and export markets.

Company Structure

Cannasouth Limited is the parent company and 100% owner of subsidiary company Cannasouth Bioscience Limited, a biopharmaceutical company that researches, develops and supplies medicinal cannabis products. In addition, the Group has investments in two joint ventures: Cannasouth Cultivation Ltd (for flower production) and Midwest Pharmaceuticals NZ Ltd (for medicines grade production and cannabinoid oil extraction services).



Governance



Tony Ho
Independent Non-Executive
Chairman (CSL)



Christine Pears
Independent Non-Executive
Director (CSL)



Juliet Hull
Independent Non-Executive
Director (CSL)



Mark Lucas
Executive Director (CSL, CBL, CCL,
MW) and Chief Executive Officer

Share Information

As at 30 June 2021	
NZX Main Board Code:	CBD
Share Price:	\$0.485
Shares on issue:	121,830,551
Market capitalisation:	\$59,088,000
Financial year-end:	31 December

Executive

For biographies, refer to the website <https://www.cannasouth.co.nz/about/our-team/>



Mark Lucas
Chief Executive Officer



Mark Balchin
Chief Manufacturing Officer



Colin Foster
Chief Financial Officer
and Company Secretary



Brenda van Zyl
Business Advisor



David Gill
Chief Scientific Officer



John Sanders
Chief Commercial Officer



Kate Flynn
Portfolio Manager

Company Information:

Cannasouth Limited
Core Facilities Building
Waikato Innovation Park
1 Melody Lane
Hamilton East
Hamilton 3216
Phone: +64 7 949 8393
Email: enquiries@cannasouth.co.nz

Investor Enquiries:

Niki Mills
Head of Shared Service Department (Investor Relations Officer)
Phone: +64 7 949 8393
Email: enquiries@cannasouth.co.nz

For Shareholder Support Services:

Link Market Services Limited
Email: enquiries@linkmarketservices.com
Phone: +64 9 375 5998
Fax: +64 9 375 5990

LEARN MORE AT
CANNASOUTH.CO.NZ

enquiries@cannasouth.co.nz
+64 (0)7 949 8393

   @cannasouth

Gallagher Core Facilities Building,
Waikato Innovation Park,
1 Melody Lane, Hamilton East,
Hamilton 3216, New Zealand

PO Box 28132,
Rototuna,
Hamilton 3256,
New Zealand